{"id":4252,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2014-01-14","marketCap":19.878793716430664,"name":"BioVie Inc","phone":"17758883162","outstanding":61.16999816894531,"symbol":"BIVI","website":"https://www.bioviepharma.com/","industry":"Biotechnology"},"price":2.8875,"year":2024,"month":8,"day":17,"weekday":"Saturday","title":"Impact of interest rate fluctuations on BioVie Inc stock's performance and valuation","date":"2024-08-17","url":"/posts/2024/08/17/BIVI","content":[{"section":"1. Borrowing Costs","text":"Interest rate fluctuations directly affect BioVie Inc's borrowing costs. When interest rates are low, the company can borrow capital at lower interest rates, reducing its interest expenses and potentially increasing profitability. Conversely, when interest rates rise, borrowing costs increase, which can put pressure on BioVie Inc's profit margins."},{"section":"2. Discount Rates","text":"Interest rate fluctuations also impact the discount rates used to value BioVie Inc's future cash flows. Discount rates represent the opportunity cost of investing in the company's stock, and they are inversely related to interest rates. When interest rates rise, discount rates increase, leading to lower present values for future cash flows. This can result in a decrease in BioVie Inc's stock valuation."},{"section":"3. Investor Sentiment","text":"Interest rate fluctuations can affect investor sentiment towards BioVie Inc and the broader stock market. In a low-interest-rate environment, investors may be more inclined to invest in riskier assets like stocks, potentially driving up the demand for BioVie Inc stock and pushing its price higher. Conversely, when interest rates rise, investors may shift towards safer investments, which can negatively impact BioVie Inc's stock performance."},{"section":"4. Economic Growth","text":"Changes in interest rates often reflect changes in the broader economic conditions. When interest rates are raised due to strong economic growth, it can be a positive signal for BioVie Inc as it indicates potential market expansion, increased consumer spending, and improved business prospects. Conversely, falling interest rates may indicate economic weakness and negatively influence BioVie Inc's stock performance."},{"section":"5. Monetary Policy","text":"Interest rate fluctuations are driven by monetary policy decisions made by central banks. For example, when central banks aim to stimulate economic growth, they may lower interest rates. Such accommodative monetary policy can boost stock market performance, including BioVie Inc's stock. Conversely, tightening monetary policy and higher interest rates may dampen stock performance."},{"section":"6. Risk Management","text":"Interest rate fluctuations introduce additional risk factors that BioVie Inc and its investors need to manage. The company may implement hedging strategies to mitigate the impact of interest rate changes, such as entering into interest rate swaps or fixing interest rates on borrowings. However, these risk management efforts may come with associated costs and may not completely eliminate the potential negative impact of interest rate fluctuations."},{"section":"7. Impact on Debt Financing","text":"BioVie Inc may rely on debt financing to fund its operations or expansion plans. Interest rate fluctuations can influence the availability and cost of debt financing. Higher interest rates can make it more expensive for the company to borrow, potentially limiting its growth opportunities. Conversely, lower interest rates can make debt financing more attractive and facilitate BioVie Inc's expansion plans."},{"section":"8. Market Sentiment and Macro Factors","text":"Lastly, interest rate fluctuations can influence overall market sentiment and macroeconomic factors that impact BioVie Inc's stock performance and valuation. For example, rising interest rates may signal higher inflation expectations, which can impact consumer purchasing power and affect BioVie Inc's business operations and revenue growth."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1723550400,"headline":"BioVie to Present Overview of Bezisterim Clinical Data on Longevity at 11th Aging Research and Drug Discovery Meeting","id":129332867,"image":"https://media.zenfs.com/en/globenewswire.com/59b6a6238f0916635550f83cbb1be6fe","symbol":"BIVI","publisher":"Yahoo","summary":"Presentation to showcase potential impact of bezisterim on biological age, gene expression and measures of aging-related diseases from growing body of clinical evidenceCARSON CITY, Nev., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster presentation will be shared at the 11","url":"https://finance.yahoo.com/news/biovie-present-overview-bezisterim-clinical-120000861.html"},{"category":"company","date":1723444380,"headline":"Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday","id":129312509,"image":"","symbol":"BIVI","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3597018574"},{"category":"company","date":1723111200,"headline":"BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson’s Disease","id":129233746,"image":"https://media.zenfs.com/en/globenewswire.com/59b6a6238f0916635550f83cbb1be6fe","symbol":"BIVI","publisher":"Yahoo","summary":"SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson’s disease who are naïve to carbidopa/levodopa Company engaged in trial start-up activities and plans to initiate patient screening Q4 2024 CARSON CITY, Nev., Aug. 08, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and","url":"https://finance.yahoo.com/news/biovie-announces-alignment-fda-clinical-100000432.html"},{"category":"company","date":1723097880,"headline":"BioVie achieves alignment with FDA on upcoming SUNRISE-PD trial","id":129244126,"image":"","symbol":"BIVI","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3591765804"},{"category":"company","date":1723096800,"headline":"BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson?s Disease","id":129244128,"image":"","symbol":"BIVI","publisher":"GlobeNewswire","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=c34uaselqd"},{"category":"company","date":1723096020,"headline":"BioVie says FDA aligns with mid-stage Parkinson’s disease trial","id":129244130,"image":"","symbol":"BIVI","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3591737838"},{"category":"company","date":1722976800,"headline":"BioVie Inc. Announces Reverse Stock Split","id":129187744,"image":"https://media.zenfs.com/en/globenewswire.com/59b6a6238f0916635550f83cbb1be6fe","symbol":"BIVI","publisher":"Yahoo","summary":"Shares of BioVie common stock began trading on split-adjusted basis on August 6, 2024CARSON CITY, Nev., Aug. 06, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”) today announced that the Company's reverse stock split of its issued and outstanding Class A common stock (“Common Stock”), at an exchange ratio of 1-for-10, is now effective. The Company’s Common Stock began trading on a split-adjusted basis and will remain listed on The Nasdaq Capital Market under the sy","url":"https://finance.yahoo.com/news/biovie-inc-announces-reverse-stock-204000328.html"},{"category":"company","date":1722938901,"headline":"Individual investors invested in BioVie Inc. (NASDAQ:BIVI) copped the brunt of last week's US$55m market cap decline","id":129172066,"image":"https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","symbol":"BIVI","publisher":"Yahoo","summary":"Key Insights Significant control over BioVie by individual investors implies that the general public has more power to...","url":"https://finance.yahoo.com/news/individual-investors-invested-biovie-inc-100821643.html"},{"category":"company","date":1722923340,"headline":"BioVie announces 1-for-10 reverse stock split","id":129191437,"image":"","symbol":"BIVI","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3589003336"},{"category":"company","date":1722840600,"headline":"BioVie Inc. trading halted, news pending","id":129191439,"image":"","symbol":"BIVI","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3587389811"}]}